CLDXCelldex Therapeutics, Inc.
Price
+21%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, growth fading, the market undecided.
Celldex Therapeutics, Inc., which we refer to as “Celldex,” “we,” “us,” “our” or the “Company,” is a biopharmaceutical company dedicated to exploring the science of mast cell biology and developing therapeutic antibodies which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Celldex Therapeutics, Inc. (CLDX) reported revenue of $22K in Q2 2026 (quarter ended Jun 30, 2026), down 97% from the same quarter a year earlier. That came with net loss of $74M. For the full year FY2025, revenue was $1.5M (−78% year on year) and net income −$259M. Its largest product in Q2 2026 was Grant at $15K, 68% of the disclosed total, well ahead of Service at 32%. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 22, 2026On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of Barzolvolimab in chronic spontaneous urticaria (CSU)Other event · Form 8-K
- Aug 6, 2026Celldex Reports Second Quarter Financial Results and Provides Corporate Update.Earnings release · press release
- Jul 15, 2026On July 10, 2026, Sam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. (the “Company”), notified the Company of his plans to retire effective on or about March 31, 2027.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $22.0KThe company’s own SEC segment disclosure.
- Grant$15.0K68%
- Service$7.0K32%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.